Bryan Goodwin is currently the Vice President of Cardiorenal Strategy and Portfolio at Eli Lilly and Company in Boston, Massachusetts. They have held significant leadership roles in various companies, including Vice President and Head of Biology at Enanta Pharmaceuticals and Senior Director positions at Shire and Pfizer, where they led research efforts in multiple therapeutic areas. Bryan earned a Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Biology from the University of Sydney, completing their studies in 1999.
This person is not in any teams
This person is not in any offices